The decision marks a significant milestone after both medicines were previously made available through managed access agreements while additional evidence on their effectiveness was gathered. SMA is a ...

This means mothers whose babies need antibiotics could leave hospital sooner and complete treatment at home with full clinical support, potentially reducing their hospital stay by up to 2.7 days. All ...

Today’s final draft guidance says givinostat (also called Duvyzat and made by ITF Pharma) can be used to treat Duchenne muscular dystrophy (DMD) in people aged 6 and over who are able to walk or stand ...

There is a commercial access agreement for semaglutide. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

For decades, the little blue inhaler was a lifeline for millions of people with asthma. But doctors now know it can make the condition worse - and a quiet revolution in treatment is already ...

Evidence-based recommendations on niraparib (Zejula) for maintenance treatment of advanced (FIGO stages 3 and 4) ovarian, fallopian tube or peritoneal cancer after response to first-line ...

Evidence-based recommendations on natalizumab originator (Tysabri) and biosimilar (Tyruko) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy in adults.

Evidence-based recommendations on dostarlimab (Jemperli) with platinum-containing chemotherapy for primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair ...

NICE is unable to make a recommendation on trastuzumab deruxtecan (Enhertu) for treating hormone receptor-positive HER2-low metastatic breast cancer in adults after 2 or more endocrine treatments.

NICE is unable to make a recommendation on clascoterone (Winlevi) for treating acne vulgaris in people 12 years and over. This is because the company did not provide an evidence submission.

We have moved NG251 to become a 'NICE Review'. This is to better reflect what the purpose of this product is and to help you find relevant content more quickly. The review itself has not changed. See ...

There is a simple discount patient access scheme for nivolumab, and a patient access scheme plus commercial access agreement for ipilimumab. NHS organisations can get details on the Commercial Access ...